ERA4TB accelerates the development of new treatment regimens for tuberculosis.

Effects of the COVID-19 on the fight against tuberculosis

The general public is well aware of the tragic impact of the COVID-19 on the community in terms of lives, disruption of livelihoods and social distress. Far less obvious are the indirect effects that the outbreak exert on other major diseases of global incidence like tuberculosis. To contain the spread of the COVID-19, most countries have imposed strict lockdown measures that, however necessary, are negatively affecting the programs to eradicate tuberculosis at global level by hindering TB diagnosis, notifications and likely shortening the provision of drugs against the infection.

The Stop-TB Partnership has been working on a series of models to estimate the effect of the COVID-19 outbreak on the progress of TB at global scale. These models focus on three countries with a high burden of TB and distinct social settings that constitute paradigmatic cases within the spectrum of countries in which TB has a high incidence. In the worst-case scenario, the modelers estimated that a 3-month lockdown followed by a 10-month period to return to normality could lead to an additional 6.3 million cases of TB between 2020 and 2025, and an additional 1.4 million TB deaths during this time at global level. With these figures, the gains made in the fight against TB in the last five to eight years could be lost out. The study stresses that recovering the progress made in the last years will only be possible through increasing the efforts and investments in TB.

ERA4TB stands in solidarity with the additional difficulties that the present situation imposes on patients and professionals involved in treating TB. ERA4TB is committed with the development of new drugs of easy administration and effectivity against resistant strains, the consortium hopes to help mitigate the consequences of the COVID-19 outbreak on the battle against TB.

ERA4TB (European Regimen Accelerator for Tuberculosis) project is a public-private initiative devoted to accelerate the development of new treatment regimens for tuberculosis.

Objectives

The main objective of ERA4TB is to create a European open platform to accelerate the development of new regimens for the treatment of tuberculosis.

Ambition

All Member States of WHO and the UN have committed to the goal of ending the TB epidemic by 2030 through their unanimous endorsement of WHO’s End TB Strategy at the World Health Assembly and their adoption of the UN Sustainable Development Goals (SDGs).

Ambition

All Member States of WHO and the UN have committed to the goal of ending the TB epidemic by 2030 through their unanimous endorsement of WHO’s End TB Strategy at the World Health Assembly and their adoption of the UN Sustainable Development Goals (SDGs).

Structure

The ERA4TB platform is based on a progression pipeline that can cater for a variety of molecules at different stages of development.

News

Follow our articles and ERA4TB news

Event

ERA4TB members attend key meetings on Antimicrobial Resistance in Basel

Last week, ERA4TB members attended two key events focused on bringing together researchers and project…
Event

ERA4TB to partner with UNITE4TB for webinar focusing on community engagement in TB research

ERA4TB is delighted to be partnering with fellow IMI-funded TB research consortium, UNITE4TB, on its…
Event

6th Consortium Meeting, 25-26th January 2023 – ERA4TB partners gather for a face-to-face event in Paris

On the 25th and 26th January, more than 100 representatives of ERA4TB partners had the…

Twitter

Follow us and be the first
to know what we do

📢📢 TOMORROW 4-5pm CET📢📢

Don't miss our webinar with @UNITE4TB happening tomorrow to mark #WorldTBDay2023 on why and how to involve people affected by #tuberculosis in early-stage/pre-clinical research

👉Sign-up to attend: https://bit.ly/3yXGhIf

Only two days to go until our webinar with @UNITE4TB to mark #WorldTBday2023

We will be hearing the lived experience of a TB survivor and activist and will be exploring the benefits and challenges to community involvement in pre-clinical research
Sign-up: https://bit.ly/3Jx1IF0

We created a first-of-its-kind payment model for 2 new antimicrobials with @NHSEngland & @DHSCgovuk.

The model incentivises the development of new products while upholding antimicrobial stewardship, with payments based on value to the NHS, not volume sold https://www.nice.org.uk/news/blog/nice-leads-the-way-to-develop-a-new-approach-to-routinely-value-and-pay-for-crucial-antimicrobials

#HappeningSoon
For 4 days, the ancient city of Varanasi, India becomes the brain and heart of the global TB response.
📌Read https://mailchi.mp/stoptb.org/stop-tb-partnership-end-of-year-message-831509?e=5d5565b21a #YesWeCanEndTB #EndTB

Load More...

Know how accelerate the development of new treatment regimens for tuberculosis, discover our project

The Project